Skip to content

Collection of Blood and Urine From Patients Undergoing Radiation Therapy

Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00027326
Enrollment
1000
Registered
2001-12-03
Start date
2001-12-02
Completion date
Unknown
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Carcinoma, Tumor

Keywords

Blood, Samples, Radiation, Urine, Cancer, Natural History

Brief summary

Background: -Research in NCI's Radiation Oncology Branch depends on the availability of blood and urine samples from patients receiving radiation therapy. Objectives: -To explore the effects of radiation therapy on gene expression in white blood cells, to measure radiation damage in red blood cells and to examine changes in hormone levels in the blood and urine after radiation therapy. Eligibility: -Patients 18 years of age and older who are receiving radiation therapy. Design: * Blood and urine samples are collected when participants enter the study. * Additional samples may be collected at different times during and after treatment. Ideally, samples are obtained before, at the completion of, and 1 month following radiation therapy. Blood samples usually will be collected during routine patient monitoring procedures and will not require an additional needle stick. * A total of 300 patients will be studied at the NCI in Bethesda, MD, Johns Hopkins University in Baltimore and the University of Pennsylvania in Philadelphia.

Detailed description

BACKGROUND: Evolving research initiatives in the Radiation Oncology Branch (ROB) NCI, depend upon the availability of blood and urine samples from patients receiving radiotherapy. Examples of planned studies include an exploration of the effects of radiotherapy on peripheral leukocyte phenotype, peripheral blood protein and metabolism changes as well as measurements of matrix metalloproteinases (MMP) in urine. OBJECTIVES: This protocol provides a means of acquiring blood and urine samples in patients receiving radiation therapy for a variety of conditions. ELIGIBILITY: Patients seen in the radiation oncology clinic will be asked to donate blood and/or urine before, during and after their treatment. DESIGN: This is a pilot, exploratory study to evaluate the effects of ionizing radiation in blood and/ or urine. On most occasions, the blood samples will be obtained as a component of routine patient monitoring and will not necessitate an additional venipuncture. Blood and urine samples will be processed and stored in the Radiation Oncology Branch and Basic Research Laboratory, CCR, NCI, for use in the research efforts of the branch.

Interventions

None listed

Sponsors

National Cancer Institute (NCI)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: 1. Patients must be co-enrolled in a NIH CC protocol in which radiation will be administered. 2. Patients must be a candidate for, or currently receiving radiotherapy. 3. Age greater than or equal to 18 years. 4. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.

Exclusion criteria

1\. Patients who have unobtainable data regarding previous radiation therapy.

Design outcomes

Primary

MeasureTime frameDescription
To acquire peripheral blood and/or urine samples from patients receiving radiation therapy in the Radiation Oncology Branch, NCI.At the time of the enrollment, a blood and/or a urine sample will be collected. Blood and/or urine will also be collected at the completion of radiotherapy and at 1 month follow- up.collection of blood and urine

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKevin A Camphausen, M.D.

National Cancer Institute (NCI)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026